Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients
ABSTRACT Comorbidity factors have been reported in cancer patients to predict progression free survival (PFS) and overall survival (OS). Renal impairment (RI) is postulated as one negative prognostic factor in multiple myeloma (MM). The study aim was to detect the best way to define RI and the impact of different RI stages on MM outcome.
In this multicenter analysis, we determined RI [serum creatinine, estimated glomerular filtration rate (eGFR) by modification of diet in renal disease (MDRD) and Cockcroft-Gault] and other prognostic factors in 198 MM patients to ascertain their value on PFS and OS.
Median serum creatinine was 0.9 mg/dL in all patients, whereas the eGFR - being decreased with a median of 80 mL/min/1.73 m(2)- allowed to detect early stages of RI. Via univariate analysis, we observed increasing hazard ratios (HRs) for impaired OS with deteriorating eGFR: with eGFR(MDRD)<90 and <30, HRs were 1.3 and 2.9, respectively. Multivariate analysis determined RI with eGFR<30 and <50 as well as age >59 yr as most important variables for OS. By incorporating eGFR<30 as the most relevant factor determined via multivariate analysis and beta(2)-microglobulin (beta(2)-MG) in a novel MM-risk score, we identified patients with significantly differing OS: median survival with 0, 1 or 2 risk factors were 71, 48, and 24 months, respectively.
These findings demonstrate that RI is frequent in MM, best detected via eGFR determination and an important prognostic factor. eGFR in combination with beta(2)-MG allows definitive risk stratification with largely differing survival in MM.
SourceAvailable from: PubMed Central[Show abstract] [Hide abstract]
ABSTRACT: Multiple myeloma occurs primarily in elderly patients. Considering the high prevalence of comorbidities, comorbidity is an important issue for the management of myeloma. However, the impact of comorbidity on clinical outcomes has not been fully investigated. We retrospectively analyzed patients with newly diagnosed myeloma. Comorbidities were assessed based on the Charlson comorbidity index (CCI) and the Freiburg comorbidity index (FCI). The CCI is a summary measure of 19 comorbid conditions. FCI is determined by performance status, renal impairment, and lung disease. This study included 127 patients with a median age of 71 years. Approximately half of the patients had additional disorders at the time of diagnosis, and diabetes mellitus was the most frequent diagnosis (18.9%). The most significant factors for prognosis among patient-related conditions were a history of solid cancer and performance status (ECOG ≥ 2). The FCI score was divided into 3 groups (0, 1, and 2-3), and the CCI score was divided into 2 groups (2-3 and ≥4). FCI was a strong prognostic tool for OS (P > 0.001) and predicted clinical outcome better than CCI (P = 0.059). In conclusion, FCI was more useful than CCI in predicting overall survival in elderly patients with myeloma.BioMed Research International 01/2014; 2014:437852. DOI:10.1155/2014/437852 · 2.71 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: The neutrophil/lymphocyte ratio (NLR) at diagnosis has been shown to be a prognostic factor for survival in solid tumors. The NLR at diagnosis as a prognostic factor for multiple myeloma (MM) has not been studied. Therefore, the focus of the study was the correlation of NLR with the proven prognostic parameters in patients with MM. A total of 151 MM patients who fulfilled the International Myeloma Working Group (IMWG) criteria were enrolled in the study by a retrospective review of the patients' records. One hundred fifty-one age- and gender-matched healthy controls were also included in the study. NLR was calculated using data obtained from the complete blood count (CBC). NLR was significantly higher in MM patients than the control group (2.79 ± 1.82 vs. 1.9 ± 0.61, respectively; p < 0.0001). The median follow-up on living patients in this study was 41 months. NLR at the diagnosis was found to be an independent predictor for overall survival (OS) and event-free survival (EFS) by univariate and multivariate analysis. Patients with a NLR <2 at diagnosis experienced superior OS compared with patients with a NLR ≥2 (5-year OS rates were 87.5 and 42.4 %, respectively; p < 0.0001). In a similar fashion, superior EFS was observed in patients with a NLR <2 at the diagnosis compared with patients with a NLR ≥2 (5-year EFS rates were 88.4 and 41.8 %, respectively, p < 0.0001). This study suggests that NLR at the diagnosis is a simple, inexpensive, possible prognostic factor to assess clinical outcomes in MM patients.Annals of Hematology 12/2013; 93(5). DOI:10.1007/s00277-013-1978-8 · 2.40 Impact Factor
[Show abstract] [Hide abstract]
ABSTRACT: Das multiple Myelom ist eine Knochen- bzw. Knochenmarkerkrankung, gekennzeichnet durch die Proliferation klonaler Plasmazellen. Die Inzidenz steigt mit zunehmendem Alter. Diese Tatsache – und der Anstieg der Lebenserwartung generell – führen zu einer größer werdenden Zahl älterer Patienten mit dieser Erkrankung. In den letzten Jahren hat sich die Myelom-Therapie grundlegend verbessert, unter anderem durch die Einführung innovativer Substanzen wie Bortezomib, Thalidomid und Lenalidomid, die Optimierung der Stammzelltransplantation und der Supportivmaßnahmen. Heutzutage können auch älteren Patienten effektive, moderne und gut verträgliche Therapien angeboten werden. Für diese Patienten gilt aber, dass die Therapien dem individuellen körperlichen Allgemeinzustand angepasst werden sollen, damit Toxizitäten möglichst vermieden werden. Um ältere und häufig komorbide Myelom-Patienten mit modernen Substanzen und deren Kombinationen zu therapieren, sind insbesondere Arzneimittel zur oralen oder subkutanen Applikation relevant. Dieser Artikel bietet eine Übersicht über innovative Therapieoptionen des multiplen Myeloms und hebt insbesondere die seit 20. September 2012 in Deutschland zugelassene subkutane Bortezomib-Gabe hervor. Zusätzlich werden erste am Universitätsklinikum Freiburg erhobene Daten zur subkutanen Bortezomib-Gabe vorgestellt.Krankenhauspharmazie 11/2012; 33:467-474.